| Name | Title | Contact Details |
|---|
ASAP Medical Products Distributor is a Oxford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MusclePharm is an award winning and worldwide leading sports nutrition brand. Our expansive line of clinically proven safe and effective supplements reaches all elements of the active, push-the-edge lifestyle—from muscle building, athletic performance, weight loss and general fitness.
We are fundamentally dedicated to biopharmaceutical innovators Building a company with this unique mission requires a different philosophy. Which is why Atlantic Research Group's founders built the company on responsive and flexible points of view.
Partners Pharmacy is a long-term care pharmacy company in the United States. We offer a full range of services and resources to effectively serve the comprehensive medication needs of residents of skilled nursing facilities, assisted living communities, and alternative care facilities. Our unique AP PassPort™ has dramatically improved medication availability for residents, reduced medication management time for nursing, and improved compliance. Partners Pharmacy currently services over 40,000 beds with services areas in Connecticut, Florida, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Texas, and Virginia. Each location offers unparalleled, personalized service through the combined resources of our local teams and our expanding regional resources. Together we partner with the facilities we service to improve outcomes and reduce costs.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.